CN1839899A - Liver disease-treating medicine - Google Patents
Liver disease-treating medicine Download PDFInfo
- Publication number
- CN1839899A CN1839899A CN 200610020180 CN200610020180A CN1839899A CN 1839899 A CN1839899 A CN 1839899A CN 200610020180 CN200610020180 CN 200610020180 CN 200610020180 A CN200610020180 A CN 200610020180A CN 1839899 A CN1839899 A CN 1839899A
- Authority
- CN
- China
- Prior art keywords
- penthorum chinense
- medicine
- glycine
- methionine
- lamivudine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is a preparation for treating hepatic diseases, which is preared from Penthorum chinese Pursh and at least one selected from the following constituents: ammonium glycyrrhizinato, glycine, DL-methionine, tiopronin, Lamivudine, and Lovastatin.
Description
Technical field
The present invention relates to a kind of prescription for the treatment of the medicine of hepatopathy.
Background technology
In recent years, the clinical onset rate of hepatitis B and fatty liver has the trend that increases day by day, and the conventional eutherapeutic side effect of medicine is big, and the little curative effect of side effect is poor again.The medicine of good, side effect but also the little satisfactory to both parties treatment hepatopathy of being of no curative effect not only.
Summary of the invention
The pharmaceutical formulation that the purpose of this invention is to provide the again little treatment hepatopathy of good effect, side effect that a kind of Chinese and western drugs combines.
A kind of medicine for the treatment of hepatopathy provided by the invention is made of in following ranges by weight following raw material.By the penthorum chinense pursh extract of 5000～80000 Penthorum chinense making and at least a the making in the following component, ammonium glycyrrhizinate 25～600, glycine 25～600, DL-methionine 25～600, tiopronin 80～1000, lamivudine 35～400, lovastatin 50～640.
The medicine of aforesaid treatment hepatopathy is looked the difference of the state of an illness, and each component can have choice.The medicine of above-mentioned treatment hepatopathy is by weight by the penthorum chinense pursh extract of 15000 Penthorum chinense making and a kind of the making in the following component: tiopronin 80～800, lamivudine 20～300, lovastatin 30～400.Press the medicine of the described treatment hepatopathy of leading portion, penthorum chinense pursh extract and following component that its weight portion is made by 15000 Penthorum chinense are made ammonium glycyrrhizinate 25～600, glycine 25～600, DL-methionine 25～600.Press the medicine of the described treatment hepatopathy of leading portion, in the penthorum chinense pursh extract that its weight portion is made by 15000 Penthorum chinense, ammonium glycyrrhizinate 25～300, glycine 25～300, DL-methionine 25～300 and the following component any made tiopronin 50～600, lamivudine 25～200, lovastatin 10～80.Press the medicine of the described treatment hepatopathy of leading portion, penthorum chinense pursh extract, ammonium glycyrrhizinate 75, glycine 75, DL-methionine 75, tiopronin 100, lamivudine 35, lovastatin 50 that its weight portion is made by 15000 Penthorum chinense are made.
Wherein the extracting method of Penthorum chinense (having another name called Herba Lysimachiae Clethroids) extract is as follows: get Penthorum chinense 1000 by weight, chopping decocts with water three times, each 2 hours, collecting decoction filtered, filtrate is condensed into the clear paste that relative density is 1.15～1.18 (60～65 ℃), and cooling adds ethanol and makes and contain alcohol amount and reach 60%, stir, leave standstill, filter, precipitation is with 60% washing with alcohol three times, merge washing liquid and filtrate, reclaiming ethanol and being condensed into relative density is 1.30～1.32 thick paste.In prescription, use thick paste, in metering, press the Penthorum chinense listed as parts by weight.
Penthorum chinense has dampness removing, function of gallbladder promoting, protects the liver, heat clearing away, detoxify, fall enzyme, jaundice eliminating, invigorate blood circulation, functions such as spleen invigorating and antiviral, be the main Chinese medicinal components of treatment hepatopathy.
Tiopronin can reduce the liver cell mitochondria atpase activity, the content of ATP in the cell is raise, improve hepatocyte function, participate in hepatocyte material (albumen, sugar) metabolism simultaneously, keep hepatocyte glutathion inside concentration, suppress liver cell mitochondria lipid peroxide body and form, prevent the accumulation of triglyceride, to the transaminase who reduces chronic hepatitis have preferably short term effect especially ATP descend obviously.Can stablize protection hepatocyte such as liver plasma membrane, mitochondrial membrane.
Lamivudine is the ucleosides antiviral drugs, and lamivudine can suppress hbv replication rapidly, and (HBV) has stronger inhibitory action to hepatitis B virus.Serum transaminase is reduced.The process that stops hepatic fibrosis.
Ammonium glycyrrhizinate, glycine, DL-methionine have antiinflammatory, protection liver plasma membrane, immunomodulating, antiviral anti-hepatic fibrosis, suppress many-sided effect such as canceration of hepatic cell, regulating cell apoptosis, anticomplementary.ALT, AST take a turn for the better synchronously, have significantly to fall enzyme and jaundice eliminating effect.The treatment chronic hepatitis B is evident in efficacy.Glycine, DL-methionine have the effect of the aldosterone of inhibition,
Lovastatin suppresses the rate-limiting enzyme hydroxyl first glutaryl CoA reductase in the cholesterol building-up process in vivo competitively, make the synthetic minimizing of cholesterol, also make the synthetic increase of low density lipoprotein receptor, main site of action is at liver, the result reduces cholesterolemia and low-density lipoprotein cholesterol level, thus to the control generation effect of atherosclerosis and coronary heart disease.This product also reduces serum triglyceride level and increases the blood hdl level.Clinical hypercholesterolemia and the combined hyperlipidemia familial of being used for the treatment of of lovastatin.
Can be that penthorum chinense pursh extract and ammonium glycyrrhizinate, glycine, DL-methionine are used in prescription, also can add in tiopronin, lamivudine, the lovastatin any again and be used.Can also be that penthorum chinense pursh extract any separately and in the tiopronin, lamivudine, lovastatin is used.Look the state of an illness and medication.
The extract of Penthorum chinense, ammonium glycyrrhizinate, glycine, DL-methionine add that lovastatin is splendid to treatment fatty liver curative effect.The extract of Penthorum chinense, ammonium glycyrrhizinate, glycine, DL-methionine add tiopronin, and lamivudine is splendid to treatment hepatitis B curative effect.
Medicine by this prescription can be made into various dosage forms: granule, and oral liquid, tablet, capsule, effervescent tablet, easy to use, evident in efficacy to treatment chronic hepatitis B and fatty liver.
The present invention treats the good effect of liver disease drug: the medicine by this prescription has stronger inhibitory action to hepatitis B virus.Serum transaminase is reduced.The process that stops hepatic fibrosis.Cholesterolemia and low-density lipoprotein cholesterol level are reduced, thus atherosclerosis and coronary heart disease are had preventive and therapeutic effect.Can suppress liver cell mitochondria lipid peroxide body and form, prevent the accumulation of triglyceride, evident in efficacy to fatty liver.
Below be the case of taking treatment liver disease drug provided by the invention:
First example: king XX, the woman, 28 years old, suffer from hepatitis B, the compatibility of the extract of employing Penthorum chinense, ammonium glycyrrhizinate, glycine, DL-methionine is treated every day three times, continuous use 4 months, treatment back clinical symptoms, Signs disappear, and total bilirubin (TBIL), glutamate pyruvate transaminase (ALT) drop to normally.Check does not have knock-on after the drug withdrawal.I.e. recovery from illness.
Second example: open XX, the man 47 years old, suffers from fatty liver, adopt the extract of Penthorum chinense, the compatibility of lovastatin to treat every day three times, continuous use 3 months, treatment back symptom and sign disappear, and it is normal that ALT, AST recover, and ultrasound diagnosis liver form and essence echo are normal.I.e. recovery from illness.
The 3rd example: square XX, the man, 36 years old, ill viral hepatitis b adopts the prescription of penthorum chinense pursh extract, tiopronin compatibility to treat every day three times, continuous use 3 months, treatment back symptom, each symptom of sign are divided into disappearance, and liver function ALT, AST, TBIL and DBTL etc. are divided into again normal, and untoward reaction is not arranged in the therapeutic process.I.e. recovery from illness.
The 4th example: civilian XX, the woman, 18 years old, ill viral hepatitis b adopts the prescription of penthorum chinense pursh extract, lamivudine compatibility to treat every day three times, continuous use 2 months, treatment back symptom, each symptom of sign are divided into disappearance, and liver function ALT, AST, TBIL and DBTL etc. are divided into again normal, no rebound phenomenon.I.e. recovery from illness.
The 5th example: Peng XX, the man, 43 years old, ill viral hepatitis b, adopt the compatibility of penthorum chinense pursh extract, lamivudine, ammonium glycyrrhizinate, glycine, DL-methionine to treat every day three times, continuous use 1 month, treatment back clinical symptoms, Signs disappear, and total bilirubin (TBIL), glutamate pyruvate transaminase (ALT) drop to normally.Check does not have knock-on after the drug withdrawal.I.e. recovery from illness.
The 6th example: old X, the woman, 25 years old, ill viral hepatitis b, adopt the compatibility of penthorum chinense pursh extract, tiopronin, ammonium glycyrrhizinate, glycine, DL-methionine to treat every day three times, continuous use 1 month, treatment back clinical symptoms, Signs disappear, and total bilirubin (TBIL), glutamate pyruvate transaminase (ALT) drop to normally.Check does not have knock-on after the drug withdrawal.I.e. recovery from illness.
The specific embodiment
The embodiment of the invention sees Table 1, table 2, table 3.
Table 1
Table 2
Table 3
Claims (5)
1. medicine for the treatment of hepatopathy, it is characterized in that by weight by the penthorum chinense pursh extract of 5000～80000 Penthorum chinense making and at least a the making in the following component, ammonium glycyrrhizinate 25～600, glycine 25～600, DL-methionine 25～600, tiopronin 80～1000, lamivudine 35～400, lovastatin 50～640.
2. by the medicine of the described treatment hepatopathy of claim 1, it is characterized in that by weight by the penthorum chinense pursh extract of 15000 Penthorum chinense making and a kind of the making in the following component, tiopronin 80～800, lamivudine 20～300, lovastatin 30～400.
3. by the medicine of the described treatment hepatopathy of claim 1, it is characterized in that making ammonium glycyrrhizinate 25～600, glycine 25～600, DL-methionine 25～600 by the penthorum chinense pursh extract and the following component of the making of 15000 Penthorum chinense by weight.
4. press the medicine of the described treatment hepatopathy of claim 1, in penthorum chinense pursh extract, ammonium glycyrrhizinate 25～300, glycine 25～300, DL-methionine 25～300 and the following component that it is characterized in that being made by 15000 Penthorum chinense by weight any made tiopronin 50～600, lamivudine 25～200, lovastatin 10～80.
5. by the medicine of the described treatment hepatopathy of claim 1, it is characterized in that making by penthorum chinense pursh extract, ammonium glycyrrhizinate 75, glycine 75, DL-methionine 75, tiopronin 100, lamivudine 35, the lovastatin 50 of the making of 15000 Penthorum chinense by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610020180 CN1839899A (en) | 2006-01-19 | 2006-01-19 | Liver disease-treating medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610020180 CN1839899A (en) | 2006-01-19 | 2006-01-19 | Liver disease-treating medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1839899A true CN1839899A (en) | 2006-10-04 |
Family
ID=37029202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610020180 Pending CN1839899A (en) | 2006-01-19 | 2006-01-19 | Liver disease-treating medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1839899A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101120958B (en) * | 2007-03-13 | 2010-11-10 | 泸州医学院 | Medicinal preparation for treating liver cancer and leukemia and producing technology thereof |
| CN101822686B (en) * | 2010-02-02 | 2012-04-18 | 邓学峰 | Cefpirome sulfate combined drug |
-
2006
- 2006-01-19 CN CN 200610020180 patent/CN1839899A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101120958B (en) * | 2007-03-13 | 2010-11-10 | 泸州医学院 | Medicinal preparation for treating liver cancer and leukemia and producing technology thereof |
| CN101822686B (en) * | 2010-02-02 | 2012-04-18 | 邓学峰 | Cefpirome sulfate combined drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1259935C (en) | Medicine for treating hyperlipemia | |
| CN102159227A (en) | Pharmaceutical composition for purifing vein and preparation method thereof | |
| CN1824177A (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN102166330A (en) | Medicament for treating hyperlipidemia and preparation thereof | |
| CN102697982B (en) | Composition having auxiliary blood fat reducing effect and preparation method thereof | |
| CN1839899A (en) | Liver disease-treating medicine | |
| CN100341547C (en) | Medicinal composition for regulating blood fat, prepn. method and use thereof | |
| CN101167782B (en) | Momordica grosvenori liver-protecting preparation and production method thereof | |
| CN1565467B (en) | Use of cornel and its extract in preparation alpha-glucosidase inhibitor medicine | |
| CN1895623A (en) | Medicinal composition for treating fatty liver, its preparation and use | |
| CN100394953C (en) | Fat-reducing health-care product | |
| CN100363046C (en) | Prepn for treating fatty liver and alcoholic liver and its prepn process | |
| CN100464755C (en) | Traditional Chinese medicine preparation with functions of immunological regulation for anti-chemical damage | |
| CN106138164A (en) | A kind of compound Chinese medicinal preparation with Adjust-blood lipid function | |
| CN1049349C (en) | Chinese herb medicinal liquid for curing dropsy | |
| CN104622877A (en) | Application of 20(R)-ginsenoside Rg3 in preparation of medicine for treating hyperlipidemia | |
| CN1730090A (en) | Chinese traditional medicinal composition for treating hepatitis and process for preparing the same | |
| CN1706453A (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN1159029C (en) | Blood lipoid regulating medicine and its prepn | |
| CN100571726C (en) | A kind of pharmaceutical composition | |
| CN108420842A (en) | A kind of sowthistle-leaf ixeris seedling preparation of antigout effect | |
| CN1539844A (en) | 2,3,5,4'-tetrahydroxy diphenyl ethylene-2-1-beta-D-glucoside | |
| CN1276761C (en) | Compound traditional Chinese and western medicine for treating rheumatism and osteoarthritis and productive method thereof | |
| CN103784489B (en) | A kind of Radix Aucklandiae extract and its preparation method and application | |
| CN100371001C (en) | Usage of rhubarb root and its extractions in the process for preparing postprandial blood sugar decreasing medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |